ATE210447T1 - Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen - Google Patents
Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungenInfo
- Publication number
- ATE210447T1 ATE210447T1 AT95935444T AT95935444T ATE210447T1 AT E210447 T1 ATE210447 T1 AT E210447T1 AT 95935444 T AT95935444 T AT 95935444T AT 95935444 T AT95935444 T AT 95935444T AT E210447 T1 ATE210447 T1 AT E210447T1
- Authority
- AT
- Austria
- Prior art keywords
- cck
- sleep disorders
- receptor antagonists
- treat sleep
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9420703A GB9420703D0 (en) | 1994-10-14 | 1994-10-14 | Medicament |
GB9420704A GB9420704D0 (en) | 1994-10-14 | 1994-10-14 | Medicaments |
GB9423098A GB9423098D0 (en) | 1994-11-16 | 1994-11-16 | Medicaments |
PCT/EP1995/004024 WO1996011689A1 (en) | 1994-10-14 | 1995-10-12 | Use of cck-b receptor antagonists for the treatment of sleep disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE210447T1 true ATE210447T1 (de) | 2001-12-15 |
Family
ID=27267429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95935444T ATE210447T1 (de) | 1994-10-14 | 1995-10-12 | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US6413930B1 (de) |
EP (1) | EP0785788B1 (de) |
JP (1) | JPH10511928A (de) |
AT (1) | ATE210447T1 (de) |
AU (1) | AU3745795A (de) |
DE (1) | DE69524623T2 (de) |
ES (1) | ES2171196T3 (de) |
IL (1) | IL115589A0 (de) |
WO (1) | WO1996011689A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU715611B2 (en) | 1995-12-11 | 2000-02-03 | New England Medical Center Hospitals, Inc., The | Assay for and uses of peptide hormone receptor ligands |
US5750353A (en) * | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
AU3591697A (en) * | 1996-07-02 | 1998-01-21 | Merck & Co., Inc. | Method for the treatment of preterm labor |
US5929071A (en) * | 1996-07-02 | 1999-07-27 | Merck & Co., Inc. | Method for the treatment of preterm labor |
EP1392262A1 (de) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Verabreichung von arzneimittel-estern durch inhalation |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
GB0310864D0 (en) * | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
US20050079166A1 (en) | 2003-05-21 | 2005-04-14 | Alexza Molecular Delivery Corporation | Self-contained heating unit and drug-supply unit employing same |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
EP2121088B1 (de) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
DE69319945T2 (de) * | 1992-01-21 | 1999-03-11 | Glaxo Wellcome S.P.A., Verona | 1,5-Benzodiazepinderivate und deren Verwendung in Heilmittel |
TW213901B (de) * | 1992-01-27 | 1993-10-01 | Pfizer |
-
1995
- 1995-10-12 WO PCT/EP1995/004024 patent/WO1996011689A1/en active IP Right Grant
- 1995-10-12 AT AT95935444T patent/ATE210447T1/de not_active IP Right Cessation
- 1995-10-12 DE DE69524623T patent/DE69524623T2/de not_active Expired - Fee Related
- 1995-10-12 JP JP8512933A patent/JPH10511928A/ja not_active Withdrawn
- 1995-10-12 ES ES95935444T patent/ES2171196T3/es not_active Expired - Lifetime
- 1995-10-12 AU AU37457/95A patent/AU3745795A/en not_active Abandoned
- 1995-10-12 US US08/809,734 patent/US6413930B1/en not_active Expired - Fee Related
- 1995-10-12 IL IL11558995A patent/IL115589A0/xx unknown
- 1995-10-12 EP EP95935444A patent/EP0785788B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69524623T2 (de) | 2002-08-08 |
WO1996011689A1 (en) | 1996-04-25 |
JPH10511928A (ja) | 1998-11-17 |
ES2171196T3 (es) | 2002-09-01 |
DE69524623D1 (de) | 2002-01-24 |
EP0785788A1 (de) | 1997-07-30 |
AU3745795A (en) | 1996-05-06 |
IL115589A0 (en) | 1996-01-19 |
EP0785788B1 (de) | 2001-12-12 |
US6413930B1 (en) | 2002-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE225176T1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
ATE209047T1 (de) | Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen | |
ATE365042T1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
DE69922914D1 (de) | Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux | |
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69925571D1 (de) | Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems | |
ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
DE69836752D1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
DE3780972D1 (de) | Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration. | |
ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
DE69634951D1 (de) | Topische verwendung von betulinsäure zur behandlung bösartiger melanome | |
DE59810761D1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
DE69738613D1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
DE3650647D1 (de) | Arzneimittel zur Behandlung von Anxietas | |
DE69711078D1 (de) | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz | |
DE69432595D1 (de) | Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen | |
DE59209728D1 (de) | VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN | |
ATE190839T1 (de) | Verwendung von prodelphidinen zur behandlung von arthrose | |
ATE269705T1 (de) | Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen | |
DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
ID23175A (id) | Penggunaan benzopiranol untuk mengobati gangguan syaraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |